2023
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial
Grivas P, Park S, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullén A, Loriot Y, Sridhar S, Yamamoto Y, Petrylak D, Sternberg C, Gupta S, Huang B, Costa N, Laliberte R, di Pietro A, Valderrama B, Powles T. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. European Urology 2023, 84: 95-108. PMID: 37121850, DOI: 10.1016/j.eururo.2023.03.030.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Transitional CellCisplatinDeoxycytidineHumansUrinary BladderUrinary Bladder NeoplasmsConceptsBest supportive careProgression-free survivalAdvanced urothelial carcinomaPlatinum-based chemotherapyOverall survivalHazard ratioUrothelial carcinomaAnalysis of OSFirst-line maintenance therapyRelevant subgroupsCox proportional hazards modelClinical subgroup analysisPhase 3 trialKaplan-Meier methodProportional hazards modelFirst-line maintenanceMetastatic UCMaintenance therapyStable diseaseSupportive careComplete responsePartial responseAdvanced cancerPD-L1Maintenance treatmentExternal Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
Halabi S, Yang Q, Roy A, Luo B, Araujo J, Logothetis C, Sternberg C, Armstrong A, Carducci M, N. K, de Bono J, Petrylak D, Fizazi K, Higano C, Morris M, Rathkopf D, Saad F, Ryan C, Small E, Kelly W. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. Journal Of Clinical Oncology 2023, 41: 2736-2746. PMID: 37040594, PMCID: PMC10414709, DOI: 10.1200/jco.22.02661.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsDocetaxelHumansMalePrognosisProportional Hazards ModelsProstatic Neoplasms, Castration-ResistantTreatment OutcomeConceptsOverall survivalPrognostic modelPrognostic groupsRisk groupsProstate cancerChemotherapy-Naïve Metastatic CastrationLow-risk prognostic groupsCastration-resistant prostate cancerPrognostic risk groupingsIntermediate-risk groupMedian overall survivalPhase III trialsGroup of patientsPrognostic risk groupsResistant prostate cancerRandomized clinical trialsTime-dependent areaDifferent treatment classesIII trialsInhibitor trialsRisk groupingClinical trialsTreatment subgroupsSpecific subgroupsTrial status
2022
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up ☆
Balar A, Castellano D, Grivas P, Vaughn D, Powles T, Vuky J, Fradet Y, Lee J, Fong L, Vogelzang N, Climent M, Necchi A, Petrylak D, Plimack E, Xu J, Imai K, Moreno B, Bellmunt J, de Wit R, O’Donnell P. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up ☆. Annals Of Oncology 2022, 34: 289-299. PMID: 36494006, DOI: 10.1016/j.annonc.2022.11.012.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellCisplatinFollow-Up StudiesHumansUrinary Bladder NeoplasmsConceptsMetastatic urothelial carcinomaBlinded independent central reviewCisplatin-ineligible patientsObjective response rateRECIST version 1.1Years of followUrothelial carcinomaKEYNOTE-045KEYNOTE-052Primary endpointMost treatment-related adverse eventsResponse rateSurvival rateConfirmed objective response rateTreatment-related adverse eventsProgression-free survival ratesFurther safety concernsPlatinum-containing chemotherapyFirst-line therapyImmune checkpoint inhibitorsNew safety signalsProgression-free survivalDurability of responseFirst-line pembrolizumabOverall survival rateFORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression
Sternberg CN, Petrylak DP, Bellmunt J, Nishiyama H, Necchi A, Gurney H, Lee JL, van der Heijden MS, Rosenbaum E, Penel N, Pang ST, Li JR, del Muro X, Joly F, Pápai Z, Bao W, Ellinghaus P, Lu C, Sierecki M, Coppieters S, Nakajima K, Ishida TC, Quinn DI. FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression. Journal Of Clinical Oncology 2022, 41: 629-639. PMID: 36240478, PMCID: PMC9870218, DOI: 10.1200/jco.21.02303.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellDNAHumansPlatinumReceptor, Fibroblast Growth Factor, Type 1RNA, MessengerUrinary Bladder NeoplasmsConceptsMetastatic urothelial carcinomaUrothelial carcinomaOverall survivalComparable efficacyPan-fibroblast growth factor receptor inhibitorPhase II/III studyPrior platinum-containing regimenPhase II/IIIMRNA overexpressionGrowth factor receptor inhibitorsFGFR-directed therapiesGrade 3/4 eventsMedian overall survivalPlatinum-containing regimenPrimary end pointAdvanced urothelial carcinomaOpen-label trialDNA alterationsVersus ChemotherapyIII studyManageable safetyPlatinum chemotherapyResponse rate analysisReceptor inhibitorsInterim analysis
2006
Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone
Berry D, Moinpour C, Jiang C, Ankerst D, Petrylak D, Vinson L, Lara P, Jones S, Taplin M, Burch P, Hussain M, Crawford E. Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone. Journal Of Clinical Oncology 2006, 24: 2828-2835. PMID: 16782921, DOI: 10.1200/jco.2005.04.8207.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsDocetaxelEstramustineHumansMaleMiddle AgedMitoxantronePainPain MeasurementPalliative CarePrednisoneProstatic NeoplasmsQuality of LifeSurvival AnalysisTaxoidsConceptsPain palliationMP armProstate cancerMcGill Pain Questionnaire-Short FormPrimary patient-reported outcomesPain Questionnaire-Short FormPresent Pain Intensity scaleAndrogen-independent prostate cancerAdvanced stage prostate cancerProstate cancer moduleMedian overall survivalLife Questionnaire C30Cancer Core QualityPatient-reported outcomesSuperior clinical efficacyDisease-related symptomsStage prostate cancerPain intensity scaleQuality of lifeRandom assignmentQuestionnaire-Short FormBone painDE armAnalgesic useEligible patients
2001
Transitional cell carcinoma of the bladder: New approaches to the treatment of advanced disease
Petrylak D. Transitional cell carcinoma of the bladder: New approaches to the treatment of advanced disease. Current Oncology Reports 2001, 3: 285-286. PMID: 11389810, DOI: 10.1007/s11912-001-0076-6.Peer-Reviewed Original ResearchAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellFemaleHumansMaleRandomized Controlled Trials as TopicUrinary Bladder Neoplasms
2000
Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point.
Small E, Lew D, Redman B, Petrylak D, Hammond N, Gross H, Eastham J, Crawford E. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. Journal Of Clinical Oncology 2000, 18: 2537-44. PMID: 10893284, DOI: 10.1200/jco.2000.18.13.2537.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Transitional CellFemaleHumansMaleMiddle AgedPaclitaxelSurvival RateUrologic NeoplasmsConceptsAdvanced transitional cell carcinomaTransitional cell carcinomaCombination of paclitaxelSurvival timeMedian progression-free survival timeNeoadjuvant platinum-based therapySouthwest Oncology Group studyProgression-free survival timeClinical trial end pointsGrade 4 toxicityPoor prognostic featuresTrial end pointsEnrollment of patientsMedian survival timeOverall survival timeCooperative group settingPlatinum-based therapyResponse proportionsAcceptable toxicityExtranodal diseaseNeoadjuvant therapyNeurologic toxicityComplete responsePartial responsePrognostic featuresColitis and docetaxel-based chemotherapy
Kreis W, Petrylak D, Savarese D, Budman D. Colitis and docetaxel-based chemotherapy. The Lancet 2000, 355: 2164. PMID: 10902651, DOI: 10.1016/s0140-6736(05)72789-6.Peer-Reviewed Original ResearchAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsClinical Trials as TopicColitisDiarrheaDocetaxelEstramustineFemaleHumansMalePaclitaxelProstatic NeoplasmsTaxoidsVinblastineVinorelbineTHE EFFECT OF CYSTECTOMY, AND PERIOPERATIVE METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN CHEMOTHERAPY ON THE RISK AND PATTERN OF RELAPSE IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER
ENNIS R, PETRYLAK D, SINGH P, BAGIELLA E, O’TOOLE K, BENSON M, OLSSON C. THE EFFECT OF CYSTECTOMY, AND PERIOPERATIVE METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN CHEMOTHERAPY ON THE RISK AND PATTERN OF RELAPSE IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. Journal Of Urology 2000, 163: 1413-1418. PMID: 10751847, DOI: 10.1016/s0022-5347(05)67632-x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinCombined Modality TherapyCystectomyDisease-Free SurvivalDoxorubicinFemaleHumansMaleMethotrexateMiddle AgedMuscle NeoplasmsMuscle, SmoothNeoplasm InvasivenessNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasm StagingRetrospective StudiesRisk FactorsTreatment FailureUrinary Bladder NeoplasmsVinblastineConceptsRelapse-free survivalMuscle-invasive bladder cancerM-VAC chemotherapyLow-risk patientsInvasive bladder cancerRisk patientsPelvic failurePelvic relapseCisplatin chemotherapyBladder cancerMultivariate analysisIndependent poor prognostic factorCox proportional hazards modelMUSCLE INVASIVE BLADDERBenefit of chemotherapyHigh-risk featuresHigh-risk patientsPatterns of relapsePelvic lymph nodesKaplan-Meier methodPoor prognostic factorAmerican Joint CommitteePathological stage T3Proportional hazards modelExcellent disease controlAndrogen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
Hussain M, Fisher E, Petrylak D, O’Connor J, Wood D, Small E, Eisenberger M, Crawford E. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study. Journal Of Clinical Oncology 2000, 18: 1043-9. PMID: 10694555, DOI: 10.1200/jco.2000.18.5.1043.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAndrogensAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsDisease ProgressionDrug Administration ScheduleFeasibility StudiesGoserelinHumansHydrocortisoneLeuprolideMaleMiddle AgedOrchiectomyProstatic NeoplasmsSuraminTreatment OutcomeConceptsMetastatic prostate cancerAndrogen deprivationProstate cancerTreatment interruptionGrade 3Southwest Oncology Group studyCombination of suraminTherapy-related deathsGrade 4 toxicityCooperative group settingTreatment of patientsNumber of patientsFeasibility of treatmentAdequate hematologicOverall survivalCoagulation parametersDisease progressionSuramin treatmentPatientsSecond courseTreatment cyclesMultiple coursesCancerSuraminSuch treatment
1999
Chemotherapy for advanced hormone refractory prostate cancer
Petrylak D. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999, 54: 30-35. PMID: 10606282, DOI: 10.1016/s0090-4295(99)00452-5.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsCell DeathClinical Trials as TopicHumansMaleNeoplasms, Hormone-DependentProstatic NeoplasmsSurvival RateConceptsHormone-refractory prostate cancerRefractory prostate cancerProstate-specific antigenProstate cancerBone painAdvanced hormone-refractory prostate cancerHormone-resistant prostate cancerSerum prostate-specific antigenCombination of estramustinePhase III studySoft tissue metastasesTaxane-based therapyCombination of mitoxantroneMetastatic prostate cancerDrug Administration approvalCorticosteroid therapyHormone therapyIII studyTissue metastasesRandomized trialsTreatment optionsHistorical controlsAdministration approvalClinical practiceUS FoodDocetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Hussain M, Petrylak D, Fisher E, Tangen C, Crawford D. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Seminars In Oncology 1999, 26: 55-60. PMID: 10604271.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsClinical Trials, Phase III as TopicDocetaxelEstramustineHumansMaleMitoxantroneNeoplasms, Hormone-DependentPaclitaxelPrednisoneProstatic NeoplasmsRandomized Controlled Trials as TopicTaxoidsConceptsHormone-refractory prostate cancerProstate cancerHormone-refractory prostate cancer patientsProstate-specific antigen levelRandomized phase III trialEnd pointPrimary end pointSecondary end pointsPhase III trialsSingle institution experienceSide effect profileSouthwest Oncology GroupCombination of mitoxantroneProstate cancer patientsStandard armIII trialsOncology GroupAssessment of qualityClinical outcomesEffect profileRandomized trialsTreatment armsAntigen levelsInstitution experienceCancer patientsPhase I trial of docetaxel with estramustine in androgen-independent prostate cancer.
Petrylak D, Macarthur R, O'Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, Heitjan D, Fine R, Zuech N, Sawczuk I, Benson M, Olsson C. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. Journal Of Clinical Oncology 1999, 17: 958-67. PMID: 10071290, DOI: 10.1200/jco.1999.17.3.958.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogensAntineoplastic Combined Chemotherapy ProtocolsDocetaxelDose-Response Relationship, DrugEstramustineGastrointestinal DiseasesHematologic DiseasesHumansMaleMiddle AgedPaclitaxelPainProstate-Specific AntigenProstatic NeoplasmsSurvival AnalysisTaxoidsConceptsAndrogen-independent prostate cancerEPT patientsProstate cancerMPT patientsProgressive metastatic androgen-independent prostate cancerMetastatic androgen-independent prostate cancerDose-limiting myelosuppressionGrade 3/4 granulocytopeniaPSA response ratePhase II doseDoses of docetaxelPhase I trialPharmacokinetics of docetaxelBone painMeasurable diseaseOral estramustinePo tidPain medicationPartial responseSerum PSAI trialNarcotic analgesicsTime of entryPatientsDay 1
1995
Chemotherapy for advanced renal-cell carcinoma: 1983-1993.
Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Seminars In Oncology 1995, 22: 42-60. PMID: 7855619.Peer-Reviewed Original ResearchAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellClinical Trials, Phase II as TopicDrug ResistanceFemaleHumansIncidenceKidney NeoplasmsMaleSurvival RateTreatment Outcome
1993
CYTOTOXIC CHEMOTHERAPY FOR ADVANCED RENAL CELL CARCINOMA
Yagoda A, Petrylak D, Thompson S. CYTOTOXIC CHEMOTHERAPY FOR ADVANCED RENAL CELL CARCINOMA. Urologic Clinics Of North America 1993, 20: 303-321. PMID: 8493752, DOI: 10.1016/s0094-0143(21)00489-4.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellCombined Modality TherapyHumansKidney Neoplasms
1992
Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic Cancer
Seidman A, Scher H, Petrylak D, Dershaw D, Curley T. Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic Cancer. Journal Of Urology 1992, 147: 931-934. PMID: 1371564, DOI: 10.1016/s0022-5347(17)37426-8.Peer-Reviewed Original ResearchConceptsHormone-refractory prostatic cancerProstatic cancerProgressive hormone-refractory prostate cancerElevated prostate-specific antigen levelsProstate-specific antigen levelHormone-refractory prostate cancerClinical trial end pointsOutpatient treatment regimenRefractory prostate cancerSpecific antigen levelsTrial end pointsProstate-specific antigenManageable toxicityMedian durationPartial responsePSA levelsTreatment regimenEstramustine phosphateAntigen levelsProstate cancerAdditive cytotoxicityMedian decreasePatientsSpecific antigenHuman prostate